The identification of five distinct HFpEF clusters confirms the heterogeneity of the condition and supports individualized drug therapy and tailored trial designs.
May support HFpEF phenotyping for therapy selection; leaves open validation in prospective trials before practice change.
Five distinct clusters of HFpEF patients were identified that differed in clinical characteristics, heart failure drug therapy and prognosis. These results confirm the heterogeneity of HFpEF and form a basis for tailoring trial design to individualized drug therapy in HFpEF patients.
No takes yet. Share an insight, caveat, or question.
Uijl et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: